A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease.

Trial Profile

A Study to Evaluate the Effects of MK-4305 in Patients With Chronic Obstructive Pulmonary Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Suvorexant (Primary)
  • Indications Insomnia
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Merck & Co
  • Most Recent Events

    • 31 Jul 2012 Primary endpoint amended as reported by ClinicalTrials.gov.
    • 31 Jul 2012 Actual patient number changed from 24 to 25 and actual initiation date changed from Apr 2011 to Mar 2011 as reported by ClinicalTrials.gov.
    • 12 Mar 2012 Actual end date (Feb 2012) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top